Status:
RECRUITING
Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis
Lead Sponsor:
Semmelweis University Heart and Vascular Center
Conditions:
Coronary Stent Restenosis
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The aim of this open label, randomized study is to compare the safety and efficacy of three different methods to handle coronary drug eluting stent (DES) in-stent restenosis (ISR). These are the: * ...
Eligibility Criteria
Inclusion
- Patients admitted for intervention of drug eluting stent restenosis
- Restenosis suitable for all three treatment arms as per 'instructions for use' of the devices
- Optional enrollment in the optical coherence tomography sub-study (10-20% of patients)
Exclusion
- Patients undergoing coronary angiography after sudden cardiac death
- Pregnant or nursing
Key Trial Info
Start Date :
April 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04862052
Start Date
April 26 2021
End Date
January 1 2025
Last Update
November 22 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Semmelweis University Heart and Vascular Center
Budapest, Budapest, Hungary, 1122
2
University of Szeged, Department of Invasive Cardiology
Szeged, Csongád-Csanád, Hungary, 6725